- Home
- GCMGW vs VCEL Comparison
GCMGW vs VCEL Comparison
Compare GCMGW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCMGW
- VCEL
- Stock Information
- Founded
- GCMGW 1971
- VCEL 1989
- Country
- GCMGW United States
- VCEL United States
- Employees
- GCMGW 549
- VCEL N/A
- Industry
- GCMGW Finance/Investors Services
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GCMGW Finance
- VCEL Health Care
- Exchange
- GCMGW Nasdaq
- VCEL Nasdaq
- Market Cap
- GCMGW N/A
- VCEL 2.1B
- IPO Year
- GCMGW N/A
- VCEL 1997
- Fundamental
- Price
- GCMGW $0.65
- VCEL $40.15
- Analyst Decision
- GCMGW
- VCEL Strong Buy
- Analyst Count
- GCMGW 0
- VCEL 8
- Target Price
- GCMGW N/A
- VCEL $62.00
- AVG Volume (30 Days)
- GCMGW 62.4K
- VCEL 423.4K
- Earning Date
- GCMGW 02-13-2025
- VCEL 07-31-2025
- Dividend Yield
- GCMGW N/A
- VCEL N/A
- EPS Growth
- GCMGW N/A
- VCEL 521.85
- EPS
- GCMGW 0.03
- VCEL 0.05
- Revenue
- GCMGW $514,011,999.00
- VCEL $238,541,000.00
- Revenue This Year
- GCMGW N/A
- VCEL $23.03
- Revenue Next Year
- GCMGW N/A
- VCEL $24.52
- P/E Ratio
- GCMGW $33.02
- VCEL $803.09
- Revenue Growth
- GCMGW 15.79
- VCEL 14.80
- 52 Week Low
- GCMGW $2.28
- VCEL $37.39
- 52 Week High
- GCMGW $2.50
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- GCMGW N/A
- VCEL 44.33
- Support Level
- GCMGW N/A
- VCEL $40.53
- Resistance Level
- GCMGW N/A
- VCEL $43.57
- Average True Range (ATR)
- GCMGW 0.00
- VCEL 1.62
- MACD
- GCMGW 0.00
- VCEL -0.16
- Stochastic Oscillator
- GCMGW 0.00
- VCEL 28.65
About GCMGW GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.